Danazol in treatment of angio-immunoblastic lymphadenopathy

Shripad Banavali, Prashant M. Parikh, Purvish M. Parikh, Bishan S. Charak, Alok Modi, Rajaraman Iyer, Kanchan S. Nadkarni, Tapan Saikia, R. Gopal, Chitralekna S. Soman, Suresh H. Advani
In: Cancer · 1989 · vol. 64(3) , pp. 613–615 · doi:10.1002/1097-0142(19890801)64:3<613::aid-cncr2820640308>3.0.co;2-k · PMID:2743256 · W2092120314
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper describes a patient with angio-immunoblastic lymphadenopathy who achieved complete remission using a danazol-based regimen, suggesting a potential non-cytotoxic treatment option.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The clinical manifestations of angio-immunoblastic lymphadenopathy (AILD) suggest that there is an abnormality in the immune system. Most patients with AILD die from opportunistic infections associated with lymphocyte depletion. As chemotherapy further increases the already high susceptibility of infections, the therapeutic management of AILD is difficult. The achievement of complete remission (CR) by the patient described here using a danazol-based regimen raises the hope that treatment of this disease with a noncytotoxic drug may be possible. The rationale behind and advantages of using danazol are discussed.

My notes (saved in your browser only)

Condition tags

die_deep_infiltrating

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (23)

Source provenance

openalex
last seen: 2026-05-14T06:02:11.780192+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK